FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

Дата публикации: 13-07-2026 00:07:59

TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA Approves Tauklarify (florquinitau F 18 injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease	0	17.62	14-08-2026
2	FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma	0	12.93	10-07-2026
3	FDA Approves Lytenava (bevacizumab-vikg) for the Treatment of Wet Age-Related Macular Degeneration	0	16.74	24-07-2026
4	В США одобрили применение нового препарата от болезни Альцгеймера	0	0	06-01-2023
5	U.S. Food and Drug Administration Approves an Autoinjector Version of Lerochol (lerodalcibep-liga) and Updated Indication	0	10.87	17-08-2026
6	FDA Grants Accelerated Approval to Zenbexus (iberdomide) in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for the Treatment of Multiple Myeloma	0	11.39	13-08-2026
7	FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia	0	15.63	16-07-2026
8	Eisai и Biogen подали в Японии заявку на регистрацию нового препарата от Альцгеймера	0	0	16-01-2023
9	Xeomin Approved For Expanded Indication in Pediatric Upper Limb Spasticity Patients with Cerebral Palsy Following FDA Label Update	0	10.02	26-06-2026
10	FDA accepts cemdisiran for priority review as gMG treatment	2	6	07-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.38. Источник: www.drugs.com.